Loading...
Savara Inc.
SVRA•NASDAQ
HealthcareBiotechnology
$3.07
$-0.04(-1.29%)
Savara Inc. (SVRA) Stock Overview
Explore Savara Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.47
↓ 75.29%
EPS Growth
$-0.47
↓ 45.45%
Operating Margin
-40130.88%
↓ 71.97%
ROE
-65.88%
↓ 75.29%
Dividend Yield
0.00%
Analyst Recommendations
Strong Buy
Buy
Hold
Sell
Strong Sell
Price Targets
Low$9.00
Average$10.00
High$11.00
Company Profile
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
CEO
Mr. Matthew Pauls J.D., M.B.A.
Employees
59
Headquarters
Building III, Austin, TX
Founded
2017